Kewaunee Scientific Corporation (KEQU)
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Investigation
12/08/2021
Initial Lawsuit
12/08/2021
Lawsuit Progression
05/25/2022
Was short-seller Scorpion Capital right alleging that Berkeley’s Beacon is a “$2 million black box” that “may” be committing fraud?
This post is open for investors to gather facts, and findings and track their exposure to related lawsuits. We invite investors and shareholders to contribute to this investigation for their own benefit, add events to the factual timeline below and vote on events’ pertinence.
A lawsuit was subsequently filed. We will update this post as it unfolds.
09/15/2021
Research analyst firm Scorpion Capital issued a short-selling investigative report, titled “Fleecing Customers And IPO Bagholders With A $2 Million Black Box That’s A Clunker, While Insiders and Silicon Valley Bigwigs Race To Dump Stock. Just Another VC Pump at 27X Sales. Target Price: $0.”
The report criticized the company’s technology and questioned the durability of the its most important business relationships and business growth plan. The information contained in the report was purportedly based on extensive proprietary research and analysis, including 24 research interviews with former Berkeley Lights employees, industry scientists and end users across 14 of the company’s largest customers. The report detailed a “trail of customers who allege they were ‘tricked,’ misled, or over-promised into buying a $2 million lemon” and concluded that the “reality is so far from BLI’s grandiose hype that we believe its product claims and practices may constitute outright fraud.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$26.62 | $32.76 | $-6.14 | -18.74% |
A shareholder filed a securities class action on behalf of all purchasers of Berkeley Lights common stock between July 17, 2020 and September 14, 2021, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors:
(a) that Berkeley Lights’ flagship instrument, the Beacon, suffered from numerous design and manufacturing defects including breakdowns, high error rates, data integrity issues and other problems, limiting the ability of biotechnology companies and research institutions to consistently use the machines at scale;
(b) that Berkeley Lights had received numerous customer complaints regarding the durability and effectiveness of the company’s automation systems, including complaints related to the design and manufacturing detailed in (a), above, and described herein;
(c) that the actual market for Berkeley Lights’ products and services was a fraction of the $23 billion represented to investors because of, inter alia, the relatively high cost of the company’s instruments and consumables and inability to provide the sustained performance necessary to justify these high costs; and
(d) as a result of (a)-(c), above, defendants’ statements to investors during the class period regarding Berkeley Lights’ business, operations and financial results were materially false and misleading.
05/25/2022
The court issued an order appointing the lead plaintiff and lead counsel.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.